---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-044497"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2024-04-15T23:59:59+00:00"
generated_at: "2026-06-03T23:04:55.776186+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "medium"
source: SEC EDGAR
---

# SAB Biotherapeutics completes dosing of cohort 3 for SAB-142 Phase 1 trial; no serum sickness observed

## Summary
- Completed dosing of cohort 3 in Phase 1 trial of SAB-142.
- No instances of serum sickness reported.
- Company to issue corporate update press release on or about April 16, 2024.

## SEC filing metadata
- accession: 0000950170-24-044497
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2024-04-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: medium
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000095017024044497/0000950170-24-044497-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000095017024044497/sabs-20240412.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-044497
- JSON: https://secwatch.observer/filing/0000950170-24-044497.json
- Plain text: https://secwatch.observer/filing/0000950170-24-044497.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.